Fecal transplant to help liver cancer respond to standard drugs
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have confirmed liver cancer (HCC) by scan or biopsy
- Your liver cancer can’t be removed by surgery, transplant, or local procedures
- Your liver function tests are fairly good (Child-Pugh A or B) and your health is strong enough (ECOG 0–1)
- You have measurable cancer on scans (meets RECIST criteria)
- You are eligible to receive atezolizumab plus bevacizumab as standard care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial tests whether a fecal microbiota transplant (FMT) can help overcome drug resistance in people with advanced liver cancer whose disease has worsened after a specific triple therapy (TACE, lenvatinib, and sintilimab). FMT involves transferring gut bacteria from a healthy donor to restore the balance of your gut microbiome, which may make your cancer more responsive to treatment again.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
This trial studies whether transferring healthy gut bacteria (from a donor sample) can improve outcomes for people with liver cirrhosis who have worsening complications. It may help by changing the gut microbiome, which can influence inflammation and liver health.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.